Naive Pluripotent Stem Cell Culture Medium for Stable Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPSCs) suffer from low reprogramming efficiency and stochastic outcomes, with conventional human ESCs and iPSCs exhibiting compromised pluripotency and high differentiation propensity, and there is a lack of defined conditions for isolating genetically unmodified naive human stem cells.
Innovation Solution
The development of a culture medium comprising specific inhibitors (ERK1/2, GSK3β, p38, JNK, STAT3 activators) and growth factors (bFGF, TGFβ1) supports the generation and maintenance of naive pluripotent stem cells, characterized by unmethylated XIST and high TFE3 nuclear-to-cytoplasmic expression ratio, maintaining pluripotency and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional reprogramming methods using OSKM transcription factors are applied to somatic cells, then induced pluripotent stem cells can be generated, but reprogramming efficiency remains low (up to 0.1-20%) and outcomes are highly stochastic
Solution Approach 1:
The patent applies parameter changes by modifying the reprogramming protocol to include specific small molecule inhibitors (PD0325901 for ERK1/2, CHIR99021 for GSK3β) and cytokines (LIF, bFGF, TGFβ1) that change the cellular state and signaling pathways, thereby improving reprogramming efficiency and reducing stochasticity in iPSC generation
Solution Approach 2:
The patent uses intermediary substances including ERK1/2 inhibitor PD0325901, GSK3β inhibitor CHIR99021, LIF, bFGF, and TGFβ1 as mediators that facilitate the reprogramming process by modulating signaling pathways and chromatin structure, enabling more efficient and consistent conversion of somatic cells to pluripotent state
2Reliability
If conventional human ESCs and iPSCs are used, then pluripotent cells can be obtained, but they exhibit compromised pluripotency and high differentiation propensity
Solution Approach 1:
The patent applies preliminary anti-action by pre-treating cells with ERK1/2 inhibitor PD0325901 and GSK3β inhibitor CHIR99021 before reprogramming, which prevents premature differentiation and maintains cells in a naive pluripotent state, thereby improving pluripotency stability and reducing differentiation propensity
Solution Approach 2:
The patent uses a composite culture medium system combining multiple inhibitors (PD0325901, CHIR99021), cytokines (LIF, bFGF, TGFβ1), and other additives to create an optimized environment that maintains naive pluripotent state and enhances cellular state consistency
3Productivity
If extensive cell proliferation is performed for at least one week during reprogramming, then iPSC-like cells can be generated, but the process is time-consuming and inefficient
Solution Approach 1:
The patent applies periodic action by using cyclic or pulsed treatment protocols with reprogramming factors and small molecule inhibitors, which accelerates the reprogramming process by maintaining cells in a permissive state through periodic signaling, thereby reducing reprogramming duration and time loss
Data Source
AI summary
Provided is an isolated human naive pluripotent stem cell (PSC), wherein: (i) when the naive PSC is a female PSC, then said naive female PSC has two unmethylated alleles of an X-inactive specific transcript (XIST) gene; and (ii) when said naive PSC is a male PSC, then said naive male PSC has an unmethylated allele of said XIST gene. Also provided is a culture medium which comprises an ERK1/2 inhibitor, a GSK3beta inhibitor, a p38 inhibitor, a JNK inhibitor, a STAT3 activator and at least one agent selected from the group consisting of: bFGF, TGFbeta 1, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor; or at least agent selected from the group consisting of: a TGFR inhibitor, a FGFR inhibitor, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor.